UpdatesPress Release
Vimta Labs' Q1 FY27 total income rose 13.7% YoY to ₹112.9 Cr, with PAT at ₹21.0 Cr (+11.4% YoY). Pharma services saw healthy growth.
Vimta Labs LimitedVIMTALABS · Filed with the exchange
New Biologics CRADS operations commenced.
Food testing is adapting to headwinds via domestic market penetration.
No comments yet. Be the first.